Skip to main content
Premium Trial:

Request an Annual Quote

VistaGen Gets $36M Through Sale of Majority Stake

NEW YORK (GenomeWeb News) – VistaGen Therapeutics, a developer of bioassays for drug rescue projects, has signed a strategic financing agreement that will bring in proceeds of $36 million.

Under the agreement, VistaGen will provide 72 million shares of its restricted common stock at $.50 per share to the European subsidiary of Bergamo Acquisition Corp. The deal will provide Bergamo with a majority stake in VistaGen, which currently has around 20 million shares outstanding.

South San Francisco, Calif.-based VistaGen said that it will use the proceeds to accelerate and expand its stem cell technology-based drug rescue programs using its CardioSafe 3D and LiverSafe 3D bioassay systems. The technologies are used to generate newer and safer versions of small-molecule drug candidates that have been discontinued by pharmaceutical firms due to heart or liver safety issues.

"Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," VistaGen CEO Shawn Singh said in a statement. "Upon the closing of this transformative financing, our strong long-term financial position will enhance substantially our ability to drive our core programs to valuable commercial outcomes."

VistaGen noted that the agreement with Bergamo doesn't include any warrants or investment banking fees.

The firm's shares closed Tuesday at $.75 on the OTC Markets.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.